Blue Matter Blog

Introducing our New Presentation Series on Access Evidence Generation
April 14, 2021

Generating Evidence to Support Market Access Great evidence planning is the foundation to successful market access. While good pricing and negotiation strategies at launch are essential, pharmaceutical companies can dramatically reduce the effort and risk required by having the “right” data that payers are seeking. In this case, “an ounce of prevention is really worth …

Five Trends to Watch in the European Market Access Environment
April 2, 2021

Every day, the sun rises and the sun sets. Here’s another thing that’s almost as dependable: national payers in Europe are facing increased pressures on their healthcare budgets. Payers want to provide access and fund innovative treatments to improve patient care, but they need to do so in the context of constrained budgets. However, the …